Inhibrx says combo therapy shrank more tumors than Merck's Keytruda alone

May 11, 2026 10:51 AM EDT R&D In­hi­brx says com­bo ther­a­py shrank more tu­mors than Mer­ck­'s Keytru­da alone Max Gelman Senior Editor San Diego-based biotech In­hi­brx is claim­ing that it out­per­formed Mer­ck’s Keytru­da in a dif­fi­cult-to-treat can­cer. The com­bi­na­tion of Keytru­da and In­hi­brx’s ex­per­i­men­tal drug IN­BRX-106 shrank … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER